The maker of Ozempic and Wegovy obesity drugs said some of the prices could come down, as President Trump called for drugmakers to immediately lower their prices for Medicaid. This comes as Novo Nordisk's sales showed the weakest growth in four years as the Danish drugmaker loses ground to Eli Lilly in the crucial US market for obesity drugs. Karsten Munk Knudsen spoke with Bloomberg's Francine Lacqua from Copenhagen.